Seeking Alpha HealthcareOriginal article
Spyre drops on disappointing phase 2 data for rheumatoid arthritis asset
Phase 2negativeNegative
AI Analysis
Summary
Spyre announced disappointing Phase 2 data for its rheumatoid arthritis asset, resulting in a stock decline. The company's asset failed to meet its primary endpoint in the trial.
Clinical Trial Data
Phase
2
Primary Endpoint
Not Met
Importance:7/10
Sentiment:
-0.80
Phase 2rheumatoid arthritisnegative datastock decline
Read the original article
Published by Seeking Alpha Healthcare on August 25, 2026 9:01 PM